- Home
- ILLR vs TNGX Comparison
ILLR vs TNGX Comparison
Compare ILLR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- TNGX
- Stock Information
- Founded
- ILLR 2015
- TNGX 2014
- Country
- ILLR United States
- TNGX United States
- Employees
- ILLR N/A
- TNGX N/A
- Industry
- ILLR Investment Managers
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- TNGX Health Care
- Exchange
- ILLR Nasdaq
- TNGX Nasdaq
- Market Cap
- ILLR 304.1M
- TNGX 317.4M
- IPO Year
- ILLR N/A
- TNGX N/A
- Fundamental
- Price
- ILLR $1.18
- TNGX $2.36
- Analyst Decision
- ILLR
- TNGX Strong Buy
- Analyst Count
- ILLR 0
- TNGX 8
- Target Price
- ILLR N/A
- TNGX $13.14
- AVG Volume (30 Days)
- ILLR 644.6K
- TNGX 574.3K
- Earning Date
- ILLR 03-04-2025
- TNGX 03-17-2025
- Dividend Yield
- ILLR N/A
- TNGX N/A
- EPS Growth
- ILLR N/A
- TNGX N/A
- EPS
- ILLR N/A
- TNGX N/A
- Revenue
- ILLR $45,244,000.00
- TNGX $43,383,000.00
- Revenue This Year
- ILLR N/A
- TNGX $27.73
- Revenue Next Year
- ILLR N/A
- TNGX N/A
- P/E Ratio
- ILLR N/A
- TNGX N/A
- Revenue Growth
- ILLR N/A
- TNGX 15.67
- 52 Week Low
- ILLR $0.66
- TNGX $2.35
- 52 Week High
- ILLR $8.86
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- TNGX 33.13
- Support Level
- ILLR N/A
- TNGX $2.35
- Resistance Level
- ILLR N/A
- TNGX $2.51
- Average True Range (ATR)
- ILLR 0.00
- TNGX 0.22
- MACD
- ILLR 0.00
- TNGX -0.04
- Stochastic Oscillator
- ILLR 0.00
- TNGX 0.94
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.